Marinus Pharmaceuticals Inc

Marinus Pharmaceuticals — Corporate Update (June 2016)

23 slides from Marinus Pharmaceuticals's corporate update, Jun 28, 2016

  1. Slide 1: Safe Harbor Statement

    Safe Harbor Statement To the extent that statements contained in this presentation are not descriptions of historical facts regarding Marinus, they are forward-looking statements reflecting the current beliefs and expectations of management. Words such as “may,” “will,” “expect,” “anticipate,” “esti

  2. Slide 2: Agenda

    Agenda Introduction – Christopher M. Cashman Rationale for GNX in FXS – Dr. Frank Kooy Clinical trial design & results – Dr. Julia Tsai Case summaries – Dr. Anke VanDijck Closing remarks – Christopher M. Cashman 2

  3. Slide 3: Ganaxolone: New MOA, Demonstrated Efficacy, Good Safety Data, Convenient

    3 Ganaxolone: New MOA, Demonstrated Efficacy, Good Safety Data, Convenient Goal: Improve the lives of patients with epilepsy & anxiety disorders Designed with selectivity and safety in mind New MOA Anti-seizure & anti-anxiety activity CNS-selective GABAA modulator Safety, Tolerability & Efficacy Des

  4. Slide 4: Rationale for Ganaxolone

    Rationale for Ganaxolone Dr. Frank Kooy

  5. Slide 5: Fragile X Syndrome – Disease Overview

    Fragile X Syndrome – Disease Overview Rare genetic condition Caused by mutation of the FMR1 gene on the X chromosome Most common known inherited form of intellectual disability Associated with spectrum of learning disabilities, neurological problems (seizures) and behavior difficulties (anxiety, att

  6. Slide 6: Ganaxolone in FXS Knock-Out Mouse Model

    Ganaxolone in FXS Knock-Out Mouse Model Knock-out mouse model is clinically translatable Mice exhibit increased seizure susceptibility, increased anxiety and cognitive deficits1 Phenotype is very similar to that of human fragile X FMR1 mice have deficits in GABA, causing a reduction in2: GABAA recep

  7. Slide 7: Rationale for Selecting Ganaxolone

    Rationale for Selecting Ganaxolone Anxiety and attention difficulties are seen in children with FXS Ganaxolone has been found to improve symptoms in mouse models of FXS1 and in humans Ganaxolone should increase and normalize GABAA mediated signaling by boosting the signaling capacity of existing rec

  8. Slide 8: Expectations for Study

    Expectations for Study Primary Objective: Assess safety, tolerability and efficacy of ganaxolone for treatment of anxiety and attention in patients with FXS Secondary Objective: Assess changes correlated with domains of attention, social behavior and inhibitory control using objective laboratory tes

  9. Slide 9: Proof-of-Concept Clinical Study Ganaxolone for Behaviors in Fragile X Syndrome

    Proof-of-Concept Clinical Study Ganaxolone for Behaviors in Fragile X Syndrome Dr. Julia Tsai

  10. Slide 10: Study Design

    Study Design 10 Crossover design with 1:1 ratio; N=60 2 week titration, followed by 4 week treatment in each period GNX liquid suspension dosed tid up to 36mg/kg/day (max 1800 mg/day) Primary efficacy scale: Clinical Global Impression-Improvement (CGI-I) Several secondary scales used to measure outc

  11. Slide 11: Measurement Scales

    Measurement Scales Scales Used to Measure Outcomes 11 CGI-I* PARS VAS ADAMS ABC SNAP-IV Anxiety & Attention Anxiety, Depression & Mood Clinical Improvement Behavior & Intellectual Disabilities ADHD Pediatric Anxiety *Primary endpoint was not met

  12. Slide 12: Subject Disposition

    Subject Disposition 61 Screened 59 randomized (48 UCD; 11 BG; 30 GNX 26 GNX completed Period 1 29 PBO 29 PBO completed Period 1 GNX-PBO Period 2 28 PBO-GNX Period 2 55 Completed Period 1 (Visit 4) 26 PBO-GNX Completed Period 2 25 PBO-GNX Completed Period 2 51 Completed Period 2 (Visit 7) 14

  13. Slide 13: Anxious Patient Population

    Anxious Patient Population N=29 PARS >13 PARS – clinician rated scale to assess severity of anxiety Scales designed to detect changes in anxiety, attention and hyperactivity: VAS ADAMS ABC 13

  14. Slide 14: Mean % Improvement in VAS Scale

    Mean % Improvement in VAS Scale 14 Ganaxolone vs. Placebo in Patients (with PARS >13)

  15. Slide 15: Mean % Improvement in ADAMS Scale

    Mean % Improvement in ADAMS Scale 15 Ganaxolone vs. Placebo in Patients (with PARS >13)

  16. Slide 16: Mean % Improvement in ABC Scale

    Mean % Improvement in ABC Scale 16 Ganaxolone vs. Placebo in Patients (with PARS >13)

  17. Slide 17: Anxiety is a Major Symptom in Fragile X

    Anxiety is a Major Symptom in Fragile X 17 70% Males & 56% Females are treated for Anxiety Source: Baily DB Jr, Raspa M, Olmsted M, Holiday DB. 2008. Co-occurring conditions associated with FMR1 gene variations: Findings from a national parent survey. Am J Med Genet Part A 146A-2

  18. Slide 18: Ganaxolone Safe and Well Tolerated in FXS

    Ganaxolone Safe and Well Tolerated in FXS Generally safe and well tolerated AEs consistent with other GNX studies and drug mechanism No SAEs AEs more frequent in ganaxolone than placebo: fatigue, somnolence, diarrhea, decreased appetite, rash Mild to moderate in severity, recovered without action ta

  19. Slide 19: Summary of Findings and Next Steps

    Summary of Findings and Next Steps Ganaxolone benefit on key anxiety scales for anxious FXS patients Ganaxolone was safe and generally well-tolerated in patients with FXS Results support further study of ganaxolone in FXS patients Next Steps Engage Advisors to finalize clinical and regulatory plans

  20. Slide 20: Case summaries

    Case summaries Dr. Anke Van Dijck, Sub-PI, Antwerp University Hospital, Belgium

  21. Slide 21: Why Ganaxolone in Fragile X Syndrome?

    Why Ganaxolone in Fragile X Syndrome? 21 Caused by mutation of FMR1 gene Genetic testing available Biomarker Compromised GABAA system Ganaxolone should increase and normalize GABAA mediated signaling by boosting the signaling capacity of existing receptors Mechanistic Rationale Rare genetic conditio

  22. Slide 22: Why Ganaxolone in Fragile X Syndrome?

    Why Ganaxolone in Fragile X Syndrome? * Caused by mutation of FMR1 gene * Genetic testing available Biomarker Mechanistic * Compromised GABA, system . * Ganaxolone should increase and normalize GABA, mediated Rationale signaling by boosting the signaling capacity of existing receptors + Rare genetic

  23. Slide 23: Marinus

    M&RINUS

Marinus Pharmaceuticals — Corporate Update (June 2016) on 6ix